Quantum Biopharma licensee Unbuzzd to host webinar

Mr. Zeeshan Saeed reports QUANTUM BIOPHARMA LICENSEE UNBUZZD WELLNESS TO HOST LIVE WEBINAR AND Q&A SESSION ON WEDNESDAY, OCTOBER 1, 2025 Quantum Biopharma Ltd.'s licensee, Unbuzzd Wellness Inc., the company behind unbuzzd, the scientifically proved and game-changing beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms, as part of its Regulation D 506(c) offering and up to $5-million (U.S.) raise, will host an investor webinar on Wednesday, Oct. 1, 2025, at 4:30 p.m. EST (1:30 p.m. PST). The shareholders of Quantum Biopharma will not be diluted by this offering. During the webinar, Unbuzzd chief executive officer John Duffy, adviser Jason Sawyer, medical director Dr. Eric Hoskins and board co-chair Gerry David will discuss the current investment opportunity for its scientifically backed beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms. Investors will also learn about company leadership and its path to scale distribution and retail sales. A question-and-answer session will follow the presentation. Please register. Mr. Duffy commented: "We look forward to hosting potential investors for a discussion about how Unbuzzd is changing the way the world recovers from alcohol with our clinically proven wellness and recovery consumer product. We'll also discuss the compelling opportunity for investors to be part of our success through our Regulation D 506(c) offering to raise up to $5.0-million (U.S.) to support direct-to-consumer, distributor and retail expansion plans, and establish a path to a possible initial public offering." A replay of the webinar will be available upon request by contacting [email protected] or 518-862-5993. Quantum Biopharma shareholders will not be diluted by this offering. About Quantum Biopharma Ltd. Quantum Biopharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum Biopharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum Biopharma invented unbuzzd and spun out its over-the-counter version to a company, Celly Nutrition Corp., now Unbuzzd Wellness Inc., led by industry veterans. Quantum Biopharma retains ownership of 20.10 per cent (as of June 30, 2025) of Unbuzzd Wellness. The agreement with Unbuzzd Wellness also includes royalty payments of 7 per cent of sales from unbuzzd until payments to Quantum Biopharma total $250-million. Once $250-million is reached, the royalty drops to 3 per cent in perpetuity. Quantum Biopharma retains 100 per cent of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum Biopharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property. We seek Safe Harbor.